Low glucose degradation product peritoneal dialysis regimen is associated with lower plasma EN-RAGE and HMGB-1 Proinflammatory ligands of receptor for advanced glycation end products

Therapeutic Apheresis and Dialysis

Volumn 18, Issue 3, 2014, Pages 309-316

  Opatrna, Sylvie ^a   Popperlova, Anna ^a   Kalousová, Marta ^a   Zima, Tomas ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Advanced glycation end products; Extracellular newly identified receptor for advanced glycation end products binding protein; High mobility group box 1 protein; Peritoneal dialysis; Receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; C REACTIVE PROTEIN; DIALYSIS FLUID; EXTRACELLULAR NEWLY IDENTIFIED RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS BINDING PROTEIN; GLUCOSE DEGRADATION PRODUCT; HIGH MOBILITY GROUP B1 PROTEIN; ICODEXTRIN; SOLUBLE RECEPTOR ADVANCED GLYCATION END PRODUCT RECEPTOR; UNCLASSIFIED DRUG; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; AUTACOID; GLUCAN; GLUCOSE; IMMUNOGLOBULIN RECEPTOR; LIGAND;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLEARANCE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE TOLERANCE TEST; HUMAN; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; CASE CONTROL STUDY; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; PERITONEUM; PHYSIOLOGY; PROCEDURES; TRANSPORT AT THE CELLULAR LEVEL; VERY ELDERLY; YOUNG ADULT;

AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; CASE-CONTROL STUDIES; FEMALE; GLUCANS; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HMGB1 PROTEIN; HUMANS; INFLAMMATION MEDIATORS; LIGANDS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PERITONEUM; RECEPTORS, IMMUNOLOGIC; YOUNG ADULT;

EID: 84903157840     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/1744-9987.12103     Document Type: Article

References (36)

1. Thornalley PJ. Dietary AGEs and ALEs and risk to human health by their interaction with the receptor for advanced glycation endproducts (RAGE)-an introduction. Mol Nutr Food Res 2007;51:1107-1110.
2. Thornalley PJ, Rabbani N. Highlights and hotspots of protein glycation in end-stage renal disease. Semin Dial 2009;22:400-404.
3. Thornalley PJ. Advanced glycation end products in renal failure. J Ren Nutr 2006;16:178-184.
4. Thomas MC, Tsalamandris C, MacIsaac R etal. Low-molecular-weight AGEs are associated with GFR and anemia in patients with type 2 diabetes. Kidney Int 2004;66:1167-1172.
5. Sarnak MJ, Foley RN. Cardiovascular mortality in the general population versus dialysis: a glass half full or empty? Am J Kidney Dis 2011;58:4-6.
6. Nakayama M, Kawaguchi Y, Yamada K etal. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997;51:182-186.
7. Mortier S, Faict D, Schalkwijk CG, Lameire NH, De Vriese AS. Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane. Kidney Int 2004;66:1257-1265.
8. Kalousová M, Hodková M, Kazderová M etal. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 2006;47:406-411.
9. Hou FF, Ren H, Owen WF Jr etal. Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J Am Soc Nephrol 2004;15:1889-1896.
10. Kanková K, Kalousová M, Hertlová M, Krusová D, Olsovský J, Zima T. Soluble RAGE, diabetic nephropathy and genetic variability in the AGER gene. Arch Physiol Biochem 2008;114:111-119.
11. Mirmohammadsadegh A, Tschakarjan E, Ljoljic A etal. Calgranulin C is overexpressed in lesional psoriasis. J Invest Dermatol 2000;114:1207-1208.
12. Wang H, Yang H, Tracey KJ. Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med 2004;255:320-331.
13. Forbes JM, Thorpe SR, Thallas-Bonke V etal. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 2005;16:2363-2372.
14. Basta G, Leonardis D, Mallamaci F etal. Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney Int 2010;77:225-231.
15. Nakashima A, Carrero JJ, Qureshi AR etal. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2010;5:2213-2219.
16. Kim JK, Park S, Lee MJ etal. Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis. Atherosclerosis 2012;220:208-214.
17. Yang Z, Tao T, Raftery MJ, Youssef P, Di Girolamo N, Geczy CL. Proinflammatory properties of the human S100 protein S100A12. J Leukoc Biol 2001;69:986-994.
18. Mori Y, Kosaki A, Kishimoto N etal. Increased plasma S100A12 (EN-RAGE) levels in hemodialysis patients with atherosclerosis. Am J Nephrol 2009;29:18-24.
19. Uchiyama-Tanaka Y, Mori Y, Kosaki A etal. Plasma S100A12 concentrations in peritoneal dialysis patients and subclinical chronic inflammatory disease. Ther Apher Dial 2008;12:28-32.
20. Kalousová M, Kuběna AA, Benáková H, Dusilová-Sulková S, Tesař V, Zima T. EN-RAGE (extracellular newly identified receptor for advanced glycation end-products binding protein) and mortality of long-term hemodialysis patients: a prospective observational cohort study. Clin Biochem 2012;45:556-560.
21. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418:191-195.
22. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010;28:367-388.
23. Wang H, Bloom O, Zhang M etal. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-251.
24. Cao S, Li S, Li H etal. The potential role of HMGB-1 release in peritoneal dialysis-related peritonitis. PLoS ONE 2013;8:e54647.
25. Le Poole CY, van Ittersum FJ, Valentijn RM etal. "NEPP" peritoneal dialysis regimen has beneficial effects on plasma CEL and 3-DG, but not pentosidien, CML and MGO. Perit Dial Int 2012;32:45-54.
26. Schmitt CP, von Heyl D, Rieger S etal. for the Mid European Pediatric Peritoneal Dialysis Study Group (MEPPS). Reduced systemic advanced glycation end products in children receiving peritoneal dialysis with low glucose degradation product content. Nephrol Dial Transplant 2007;22:2038-2044.
27. Zeier M, Schwenger V, Deppisch R etal. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 2003;63:298-305.
28. Erixon M, Wieslander A, Lindén T etal. 3, 4-dideoxyglucosone-3-ene in peritoneal dialysis fluids infused into the peritoneal cavity cannot be found in plasma. Perit Dial Int 2009;29(Suppl 2):S28-31.
29. Lechner M, Kratochwill K, Lichtenauer A etal. A proteomic view on the role of glucose in peritoneal dialysis. J Proteome Res 2010;9:2472-2479.
30. Foell D, Ichida F, Vogl T etal. S100A12 (EN-RAGE) in monitoring Kawasaki disease. Lancet 2003;361:1270-1272.
31. Kosaki A, Hasegawa T, Kimura T etal. Increased plasma S100A12 (EN-RAGE) levels in patients with type 2 diabetes. J Clin Endocrinol Metab 2004;89:5423-5428.
32. Zakiyanov O, Kalousová M, Kříha V, Zima T, Tesař V. Serum S100A12 (EN-RAGE) levels in patients with decreased renal function and subclinical chronic inflammatory disease. Kidney Blood Press Res 2011;34:457-464.
33. Zhu N, Yuan W, Zhou Y etal. High mobility group box protein-1 correlates with microinflammatory state and nutritional status in continuous ambulatory peritoneal dialysis patients. J Artif Organs 2011;14:125-132.
34. Davies SJ, Brown EA, Frandsen NE etal. Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription. Kidney In 2005;67:1609-1615.
35. Opatrná S, Opatrný K Jr, Racek J, Sefrna F. Effect of icodextrin-based dialysis solution on peritoneal leptin clearance. Perit Dial Int 2003;23:89-91.
36. Škrha J Jr, Kalousová M, Svarcová J etal. Relationship of soluble RAGE and RAGE ligands HMGB-1 and EN-RAGE to endothelial dysfunction in type 1 and type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2012;120:277-281.